山东药玻(600529) - 2022 Q1 - 季度财报
SPGSPG(SH:600529)2022-04-25 16:00

Financial Performance - The company's operating revenue for Q1 2022 was CNY 1,042,152,720.94, representing a year-on-year increase of 12.53%[4] - The net profit attributable to shareholders was CNY 153,203,982.25, showing a decrease of 1.93% compared to the same period last year[4] - The company's basic earnings per share for Q1 2022 was CNY 0.26[4] - Net profit attributable to shareholders for Q1 2022 was RMB 2,831,587,250.51, an increase from RMB 2,678,383,268.26 in the previous year[17] - The company's net profit for Q1 2022 was CNY 153,203,982.25, a decrease of 1.3% compared to CNY 156,226,670.04 in Q1 2021[20] - Operating profit for Q1 2022 was CNY 187,394,576.30, slightly up from CNY 186,068,031.49 in the same period last year[20] - The total comprehensive income for Q1 2022 was CNY 153,203,982.25, compared to CNY 156,226,670.04 in Q1 2021[21] - Earnings per share for Q1 2022 remained stable at CNY 0.26, consistent with Q1 2021[21] Cash Flow and Investments - The net cash flow from operating activities was negative at CNY -38,813,883.36[4] - Cash flow from operating activities for Q1 2022 was CNY -38,813,883.36, an improvement from CNY -61,359,543.88 in Q1 2021[23] - The company reported a total cash outflow from investing activities of CNY 352,535,176.88 in Q1 2022, down from CNY 683,503,476.95 in Q1 2021[23] - The cash and cash equivalents at the end of Q1 2022 stood at CNY 569,953,519.22, compared to CNY 395,907,845.81 at the end of Q1 2021, reflecting an increase of approximately 43.8%[23] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to CNY 6,465,433,169.32, reflecting a slight increase of 0.87% from the end of the previous year[5] - Current assets totaled RMB 3,290,089,360.34 as of March 31, 2022, slightly down from RMB 3,335,176,603.81 at the end of 2021[15] - Non-current assets amounted to RMB 3,175,343,808.98, an increase from RMB 3,074,538,793.72 at the end of 2021[16] - Total liabilities decreased to RMB 1,639,399,167.99 from RMB 1,739,411,613.91 at the end of 2021[17] - Shareholders' equity attributable to the parent company increased by 3.33% to CNY 4,826,034,001.33 compared to the end of the previous year[5] - Shareholders' equity increased to RMB 4,826,034,001.33 from RMB 4,670,303,783.62 at the end of 2021[17] Expenses - The company reported a significant increase in sales expenses by 144.62% due to higher freight and travel costs[9] - The company experienced a 277.37% increase in credit impairment losses, primarily due to an increase in accounts receivable[9] - Total operating costs for Q1 2022 were RMB 843,741,637.41, up 11.8% from RMB 754,319,685.85 in Q1 2021[18] - Research and development expenses for Q1 2022 were CNY 33,596,760.33, a decrease from CNY 36,357,460.15 in Q1 2021[20] - The company recorded a financial expense of CNY -646,408.91 in Q1 2022, an improvement from CNY -2,360,753.59 in Q1 2021[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 77,442[10]